Hospital
Our Lady of the Lake Hospital INC.
Our Lady of the Lake Hospital INC. was paid $205.69M by Medicaid between Jan 2018 and Dec 2024, across 405 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoOUR LADY OF THE LAKE HOSPITAL INC.
BATON ROUGE, LA 70808
BATON ROUGE, LA 70808
33aNPI1366436123assigned 09/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$205.69M
24GClaims3,827,381
24DCodes billed405
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#1 of 96
Median peer was paid$5.17M
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 434,770 | $18.76M | |
| 2019 | 516,048 | $21.53M | |
| 2020 | 419,766 | $19.05M | |
| 2021 | 593,142 | $34.50M | |
| 2022 | 668,483 | $38.25M | |
| 2023 | 690,045 | $40.16M | |
| 2024incomplete | 505,127 | $33.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 258,303 | 236,181 | $45.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 142,749 | 128,408 | $37.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 69,946 | 60,817 | $19.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 6,219 | 5,519 | $7.63M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 56,571 | 52,794 | $7.44M |
| G0378 | Hospital observation service, per hour | 3.6% | 17,401 | 12,169 | $7.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 17,856 | 15,764 | $6.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.8% | 195,348 | 173,041 | $5.77M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.4% | 193,081 | 170,851 | $4.97M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 106,491 | 86,791 | $4.85M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 71,115 | 52,657 | $3.46M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.7% | 77,011 | 68,438 | $3.45M |
393 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 106,529 | $3.23M |
| 71045 | Radiologic examination, chest; single view | 1.4% | 68,410 | $2.82M |
| 87428 | 1.4% | 108,132 | $2.81M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 73,899 | $2.64M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 102,609 | $2.53M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.2% | 4,397 | $2.42M |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 29,056 | $2.12M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 12,714 | $1.89M |
| 80053 | Comprehensive metabolic panel | <1% | 259,444 | $1.87M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,486 | $1.67M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 34,473 | $1.42M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,757 | $1.41M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 251,185 | $1.27M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 34,352 | $1.26M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 24,517 | $1.15M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,597 | $945K |
| 20610 | <1% | 1,969 | $779K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 57,138 | $751K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,188 | $749K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 51,830 | $693K |
| 36415 | Collection of venous blood by venipuncture | <1% | 304,719 | $563K |
| 84484 | <1% | 83,216 | $536K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,378 | $524K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 8,621 | $425K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 14,208 | $416K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,647 | $361K |
| 94010 | <1% | 4,021 | $358K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,774 | $354K |
| 31575 | <1% | 1,232 | $350K | |
| 73564 | <1% | 2,689 | $321K | |
| 74178 | <1% | 168 | $297K | |
| 73630 | <1% | 3,094 | $295K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 657 | $295K |
| 81025 | <1% | 42,254 | $266K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,678 | $253K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,522 | $239K |
| 74018 | <1% | 2,305 | $234K | |
| 81001 | <1% | 126,081 | $232K | |
| 90686 | <1% | 11,036 | $228K | |
| 76770 | <1% | 1,155 | $227K | |
| 92557 | <1% | 2,600 | $212K | |
| 31231 | <1% | 813 | $212K | |
| 73610 | <1% | 2,067 | $205K | |
| 83880 | <1% | 10,271 | $203K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 186 | $200K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,031 | $199K |
| 87536 | <1% | 3,548 | $193K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 851 | $190K |
| 80050 | General health panel | <1% | 5,266 | $184K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 447 | $184K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 591 | $183K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 308 | $182K |
| 72082 | <1% | 702 | $182K | |
| 73130 | <1% | 1,961 | $179K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 878 | $176K |
| 83690 | <1% | 35,741 | $173K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,017 | $158K |
| 96376 | <1% | 3,504 | $151K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 898 | $151K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 41,455 | $150K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,901 | $149K |
| 80061 | Lipid panel | <1% | 13,765 | $148K |
| 73502 | <1% | 1,987 | $148K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,118 | $143K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,928 | $130K |
| 82077 | <1% | 14,623 | $123K | |
| 73110 | <1% | 1,392 | $122K | |
| 76775 | <1% | 685 | $121K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 174 | $114K |
| 20605 | <1% | 222 | $113K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,051 | $108K |
| 87807 | <1% | 9,472 | $103K | |
| 73100 | <1% | 2,186 | $102K | |
| 92551 | <1% | 4,493 | $101K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 52,620 | $96K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 352 | $95K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 979 | $89K |
| C1776 | Joint device (implantable) | <1% | 51 | $88K |
| 74019 | <1% | 834 | $85K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 59 | $84K |
| 87070 | <1% | 10,332 | $83K | |
| 92134 | <1% | 2,759 | $81K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,037 | $77K |
| 0002A | <1% | 2,227 | $74K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,846 | $74K |
| 84703 | <1% | 12,721 | $73K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,172 | $71K |
| 73140 | <1% | 929 | $71K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 562 | $69K |
| 11719 | <1% | 1,351 | $68K | |
| 31579 | <1% | 232 | $68K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 295 | $67K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,796 | $66K |
| 95117 | <1% | 4,982 | $64K | |
| 0001A | <1% | 2,341 | $63K | |
| 73030 | <1% | 635 | $63K | |
| 90677 | <1% | 483 | $60K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,240 | $60K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 351 | $60K |
| 97597 | <1% | 1,135 | $59K | |
| 90670 | <1% | 337 | $58K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 499 | $57K |
| 88184 | <1% | 2,422 | $57K | |
| 88185 | <1% | 3,051 | $56K | |
| 73080 | <1% | 632 | $56K | |
| 96417 | <1% | 706 | $54K | |
| 95806 | <1% | 280 | $54K | |
| 97602 | <1% | 993 | $54K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 856 | $51K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 56 | $50K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 216 | $49K |
| 96367 | <1% | 1,158 | $48K | |
| 86003 | <1% | 532 | $48K | |
| 71250 | <1% | 259 | $46K | |
| 94729 | <1% | 676 | $45K | |
| 73090 | <1% | 457 | $45K | |
| 92567 | <1% | 2,072 | $45K | |
| 72100 | <1% | 342 | $45K | |
| 82550 | <1% | 11,302 | $45K | |
| 82962 | <1% | 30,250 | $44K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,390 | $43K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 185 | $42K |
| 84439 | <1% | 5,316 | $42K | |
| 92250 | <1% | 451 | $42K | |
| 73560 | <1% | 441 | $42K | |
| 92587 | <1% | 259 | $40K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 375 | $40K |
| 50590 | <1% | 92 | $40K | |
| 92523 | <1% | 306 | $39K | |
| 70486 | <1% | 61 | $39K | |
| 94060 | <1% | 440 | $39K | |
| 94726 | <1% | 532 | $38K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,228 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,457 | $37K |
| 83735 | <1% | 8,570 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,156 | $32K |
| 29580 | <1% | 566 | $32K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 268 | $32K |
| 17110 | <1% | 277 | $32K | |
| 95115 | <1% | 2,575 | $31K | |
| 81002 | <1% | 11,086 | $31K | |
| 99173 | <1% | 4,780 | $30K | |
| 87905 | <1% | 2,891 | $29K | |
| 73562 | <1% | 315 | $29K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,571 | $28K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 33 | $28K |
| 95012 | <1% | 583 | $27K | |
| 85027 | <1% | 8,836 | $27K | |
| 77073 | <1% | 170 | $26K | |
| 73620 | <1% | 314 | $26K | |
| 51798 | <1% | 528 | $26K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 216 | $25K |
| 73590 | <1% | 292 | $24K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,509 | $24K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,108 | $24K |
| 64483 | <1% | 67 | $22K | |
| 73120 | <1% | 439 | $22K | |
| 11900 | <1% | 219 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 141 | $22K |
| 92133 | <1% | 552 | $22K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 9,789 | $21K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 70 | $21K |
| 92504 | <1% | 875 | $20K | |
| 77072 | <1% | 188 | $19K | |
| 72052 | <1% | 121 | $19K | |
| 86780 | <1% | 1,933 | $19K | |
| 82043 | <1% | 4,011 | $19K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 67 | $19K |
| 99201 | <1% | 855 | $18K | |
| 92083 | <1% | 337 | $18K | |
| 73522 | <1% | 132 | $17K | |
| 96415 | <1% | 290 | $17K | |
| 83655 | <1% | 1,215 | $16K | |
| 85610 | <1% | 5,959 | $16K | |
| 86803 | <1% | 1,276 | $16K | |
| 71271 | <1% | 161 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,894 | $15K |
| 90750 | <1% | 119 | $15K | |
| 82570 | <1% | 4,550 | $15K | |
| 0003A | <1% | 448 | $15K | |
| 72070 | <1% | 123 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,698 | $14K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $13K |
| 90732 | <1% | 123 | $13K | |
| 80074 | <1% | 302 | $12K | |
| 52000 | <1% | 59 | $12K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 242 | $12K |
| 83605 | <1% | 1,956 | $12K | |
| 90656 | <1% | 1,538 | $12K | |
| 92588 | <1% | 166 | $11K | |
| 86704 | <1% | 1,105 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 43 | $11K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 19 | $11K |
| 70355 | <1% | 125 | $10K | |
| 72114 | <1% | 70 | $10K | |
| 86706 | <1% | 1,106 | $10K | |
| 80076 | <1% | 1,845 | $10K | |
| 83021 | <1% | 560 | $10K | |
| 86592 | <1% | 2,752 | $10K | |
| 25600 | <1% | 72 | $10K | |
| 72050 | <1% | 61 | $10K | |
| 85018 | <1% | 3,816 | $10K | |
| 86481 | <1% | 174 | $10K | |
| 87340 | <1% | 1,066 | $9K | |
| 86140 | <1% | 2,866 | $9K | |
| 43235 | <1% | 58 | $9K | |
| 85045 | <1% | 2,903 | $9K | |
| 55700 | <1% | 25 | $9K | |
| 92579 | <1% | 123 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,331 | $9K |
| 84153 | <1% | 508 | $9K | |
| 36430 | <1% | 55 | $9K | |
| 90734 | <1% | 79 | $8K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 53 | $8K |
| 86708 | <1% | 784 | $8K | |
| 86920 | <1% | 118 | $8K | |
| 94760 | <1% | 443 | $7K | |
| 81003 | <1% | 5,223 | $7K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 55 | $7K |
| 86709 | <1% | 764 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,990 | $7K |
| 76000 | <1% | 731 | $7K | |
| 72170 | <1% | 70 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 216 | $6K |
| 74240 | <1% | 26 | $6K | |
| 47562 | <1% | 12 | $6K | |
| 93017 | <1% | 32 | $6K | |
| 95819 | <1% | 25 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,122 | $6K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 18 | $6K |
| 52356 | <1% | 18 | $5K | |
| 90715 | <1% | 208 | $5K | |
| 82378 | <1% | 318 | $5K | |
| 82728 | <1% | 632 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 190 | $5K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 32 | $5K |
| 96409 | <1% | 48 | $5K | |
| 0004A | <1% | 150 | $5K | |
| 96411 | <1% | 77 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19,128 | $5K |
| 86850 | <1% | 902 | $4K | |
| C1769 | Guide wire | <1% | 1,028 | $4K |
| 86300 | <1% | 250 | $4K | |
| 70360 | <1% | 42 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,769 | $4K |
| 87486 | <1% | 196 | $4K | |
| 87581 | <1% | 196 | $4K | |
| 99406 | <1% | 664 | $4K | |
| 85730 | <1% | 1,255 | $4K | |
| 64721 | <1% | 18 | $4K | |
| 93970 | <1% | 12 | $4K | |
| 76870 | <1% | 13 | $4K | |
| 87641 | <1% | 122 | $4K | |
| 87040 | <1% | 454 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,129 | $3K |
| 31237 | <1% | 20 | $3K | |
| 97166 | <1% | 54 | $3K | |
| 92550 | <1% | 85 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 46,623 | $3K |
| 73000 | <1% | 46 | $3K | |
| 87640 | <1% | 124 | $3K | |
| 0071A | <1% | 75 | $3K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 148 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,599 | $2K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 67 | $2K |
| 93971 | <1% | 13 | $2K | |
| 29581 | <1% | 43 | $2K | |
| 0072A | <1% | 67 | $2K | |
| 85652 | <1% | 1,354 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 444 | $2K |
| 90746 | <1% | 32 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 172 | $2K |
| 86901 | <1% | 890 | $2K | |
| 86900 | <1% | 889 | $2K | |
| 31624 | <1% | 13 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 598 | $2K |
| L3702 | Elbow orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | <1% | 15 | $2K |
| 90756 | <1% | 97 | $2K | |
| 97803 | <1% | 87 | $2K | |
| 82553 | <1% | 252 | $2K | |
| 97162 | <1% | 30 | $2K | |
| 83718 | <1% | 185 | $2K | |
| 83615 | <1% | 302 | $2K | |
| 26720 | <1% | 12 | $1K | |
| 92610 | <1% | 88 | $1K | |
| 0124A | <1% | 83 | $1K | |
| 92552 | <1% | 31 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,322 | $1K |
| 80069 | <1% | 350 | $1K | |
| 69210 | <1% | 13 | $1K | |
| 83516 | <1% | 105 | $1K | |
| 0054A | <1% | 35 | $1K | |
| 86701 | <1% | 112 | $1K | |
| 95816 | <1% | 14 | $1K | |
| 93922 | <1% | 14 | $1K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 13 | $1K |
| C9399 | Unclassified drugs or biologicals | <1% | 307 | $1K |
| 82784 | <1% | 105 | $1K | |
| 96160 | <1% | 36 | $912.78 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 27 | $886.08 |
| 87522 | Neg quan hep c or qual rna | <1% | 26 | $796.34 |
| 73070 | <1% | 16 | $789.60 | |
| 90651 | <1% | 75 | $758.27 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,896 | $750.06 |
| 86160 | <1% | 117 | $738.11 | |
| 82465 | <1% | 186 | $737.90 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 836 | $695.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 429 | $658.61 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 407 | $628.04 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24 | $615.96 |
| 93289 | <1% | 12 | $607.92 | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 25 | $595.65 |
| 80177 | <1% | 42 | $586.99 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 14 | $584.46 |
| 82150 | <1% | 120 | $572.32 | |
| 92556 | <1% | 23 | $556.48 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 243 | $509.25 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,849 | $486.35 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,184 | $486.31 |
| 85660 | <1% | 142 | $484.88 | |
| 85007 | <1% | 222 | $480.38 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 209 | $454.30 |
| 87210 | <1% | 119 | $452.38 | |
| 90621 | <1% | 129 | $397.29 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 32 | $381.86 |
| 82607 | <1% | 28 | $367.88 | |
| 84702 | <1% | 27 | $346.15 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 171 | $342.80 |
| J3490 | Unclassified drugs | <1% | 376 | $313.86 |
| 84466 | <1% | 40 | $309.10 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 114 | $293.67 |
| 90662 | <1% | 104 | $285.11 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 52 | $265.77 |
| 86225 | <1% | 43 | $251.22 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 55 | $251.11 |
| 82652 | <1% | 15 | $249.48 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 18 | $248.00 |
| 90619 | <1% | 116 | $246.90 | |
| 94618 | <1% | 12 | $238.92 | |
| 91300 | <1% | 6,370 | $197.97 | |
| 82375 | <1% | 29 | $193.02 | |
| 85379 | <1% | 33 | $172.60 | |
| 86777 | <1% | 16 | $165.60 | |
| 82105 | <1% | 12 | $150.21 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 73 | $148.59 |
| 90480 | <1% | 15 | $147.90 | |
| 80143 | <1% | 21 | $140.22 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 56 | $127.67 |
| 83050 | <1% | 29 | $123.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 214 | $121.52 |
| 84156 | <1% | 34 | $111.56 | |
| 82977 | <1% | 12 | $105.54 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 544 | $99.67 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 19 | $97.32 |
| 82247 | <1% | 25 | $84.42 | |
| 82248 | <1% | 25 | $84.42 | |
| 92015 | Determination of refractive state | <1% | 16 | $81.78 |
| 83540 | <1% | 25 | $76.08 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 34 | $67.92 |
| 97802 | <1% | 12 | $61.80 | |
| 87205 | <1% | 32 | $52.58 | |
| 86593 | <1% | 17 | $50.29 | |
| 85014 | <1% | 17 | $34.45 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 55 | $24.87 |
| 83550 | <1% | 29 | $8.74 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,120 | $8.49 |
| 90474 | <1% | 35 | $6.28 | |
| 91305 | <1% | 118 | $0.28 | |
| 91312 | <1% | 94 | $0.28 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,741 | $0.05 |
| 90697 | 0% | 295 | $0.00 | |
| C1768 | Graft, vascular | 0% | 21 | $0.00 |
| 84132 | 0% | 613 | $0.00 | |
| 31653 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 777 | $0.00 |
| 91307 | 0% | 155 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 57 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 70 | $0.00 |
| 90680 | 0% | 67 | $0.00 | |
| 02024 | 0% | 12 | $0.00 | |
| 36832 | 0% | 21 | $0.00 | |
| 87077 | 0% | 17 | $0.00 | |
| 90671 | 0% | 97 | $0.00 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 264 | $0.00 |
| 76942 | 0% | 25 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 24 | $0.00 |
| 90633 | 0% | 71 | $0.00 | |
| 31627 | 0% | 27 | $0.00 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 38 | $0.00 |
| 90710 | 0% | 21 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 47 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 49 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPICER, CHUCK (CHIEF EXECUTIVE OFFICER)
Parent organizationFRANCISCAN MISSIONARIES OF OUR LADY HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| Our Lady of the Angels Hospital, INC. | Bogalusa, LA | $16.10M |
| Our Lady of the Angels Hospital, INC. | Bogalusa, LA | $8.94M |
| Our Lady of the Angels Clinic | Bogalusa, LA | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.